Spyre Therapeutics, Inc. (SYRE) Financials

SYRE Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 1.2 billion 71.9 million
March 31, 2026 764.0 million 93.1 million
Dec. 31, 2025 777.8 million 62.5 million
Sept. 30, 2025 504.6 million 49.5 million

SYRE Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -69.9 million 13.5 million
March 31, 2026 -57.4 million 12.8 million
Dec. 31, 2025 -44.6 million 9.8 million
Sept. 30, 2025 -37.1 million 9.6 million

SYRE Net Income

No data available :(

SYRE Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 1.1 billion - -
March 31, 2026 741.5 million - -
Dec. 31, 2025 756.5 million - -
Sept. 30, 2025 486.2 million - -

SYRE Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 84.7 million
March 31, 2026 78.5 million
Dec. 31, 2025 75.1 million
Sept. 30, 2025 60.4 million

SYRE Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 - 65.5 million 16.1 million -
March 31, 2026 - 60.4 million 15.2 million -
Dec. 31, 2025 - 44.6 million 12.5 million -
Sept. 30, 2025 - 45.2 million 11.6 million -

SYRE Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 - -
March 31, 2026 - -
Dec. 31, 2025 90.5 million 45.2 million
Sept. 30, 2025 - 45.2 million

SYRE

Price: $108.92

52 week price:
14.51
108.92

Earnings Per Share: -1.93 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 9.1 billion

Links: